Financial Performance - The company's operating revenue for Q3 2024 was ¥431,810,661.74, a decrease of 0.04% year-over-year, while the total revenue for the year-to-date reached ¥1,320,029,736.34, an increase of 3.95% compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2024 was -¥56,181,320.65, representing a significant decline of 6,060.53% year-over-year, with a year-to-date net profit of -¥40,583,766.31, down 4,511.40% from the previous year[3] - The company reported a basic earnings per share of -¥0.1415 for Q3 2024, a decrease of 5,995.83% compared to the same period last year[3] - Net profit for Q3 2024 was a loss of ¥53,179,196.56, compared to a loss of ¥9,367,185.70 in Q3 2023, indicating a significant decline in profitability[17] - The total comprehensive income attributable to the parent company for Q3 2024 was -40,583,766.31 CNY, compared to -880,075.42 CNY in the same period last year, indicating a significant decline[18] - Basic and diluted earnings per share for Q3 2024 were both -0.1026 CNY, compared to -0.0022 CNY in the same period last year, reflecting a worsening financial performance[18] - The company’s total comprehensive income for Q3 2024 was -53,179,196.56 CNY, compared to -9,367,185.70 CNY in the same period last year, indicating a significant deterioration in overall financial health[18] Assets and Liabilities - Total assets as of September 30, 2024, were ¥2,668,838,236.65, down 10.65% from the end of the previous year[3] - The company's total assets decreased to ¥2,668,838,236.65 in Q3 2024 from ¥2,986,860,553.79 in Q3 2023, a decline of 10.6%[16] - Current liabilities totaled ¥584,534,958.07 in Q3 2024, down from ¥822,828,904.46 in Q3 2023, a reduction of 28.9%[16] - Non-current liabilities decreased to ¥171,830,363.37 in Q3 2024 from ¥183,866,985.56 in Q3 2023, a decrease of 6.6%[16] - The company’s total equity attributable to shareholders decreased by 2.79% to ¥1,730,586,311.29 as of September 30, 2024[3] - The total equity attributable to shareholders of the parent company was ¥1,730,586,311.29 in Q3 2024, down from ¥1,780,316,277.50 in Q3 2023, reflecting a decrease of 2.8%[16] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥28,274,515.34, reflecting a decline of 111.05% compared to the previous year[3] - The net cash flow from operating activities for Q3 2024 was -28,274,515.34 CNY, a decrease from 255,897,207.61 CNY in the previous year, reflecting a negative trend in operational cash generation[20] - Cash received from the sale of goods and services was 1,398,283,862.09 CNY, down from 2,140,443,447.35 CNY year-over-year, showing a decline of approximately 34.6%[19] - The total cash outflow from operating activities was 1,447,746,643.99 CNY, compared to 1,918,152,212.02 CNY in the previous year, indicating a decrease of approximately 24.5%[20] - The net cash flow from investing activities improved by 89.35%, amounting to -48,504,864.53 RMB, compared to -455,614,862.11 RMB in the previous year, mainly due to reduced expenditures on long-term assets and financial investments[9] - The net cash flow from financing activities was -99,502,338.88 RMB, a significant decrease of 210.53% from 90,018,876.26 RMB in the same period last year, attributed to increased repayments of bank loans and cash buybacks of company stock[9] - The company’s total cash inflow from financing activities was 126,410,000.00 CNY, compared to 367,055,000.00 CNY in the previous year, reflecting a decrease of approximately 65.6%[20] Research and Development - The company’s R&D expenses for the first nine months of 2024 were ¥44,916,908.61, an increase of 37.36% compared to ¥32,701,057.63 in the same period of 2023[7] - Research and development expenses increased to ¥44,916,908.61 in Q3 2024, up from ¥32,701,057.63 in Q3 2023, representing a growth of 37.3%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 28,060, with the largest shareholder, Shanghai Lanwei Investment Co., Ltd., holding 37.34% of shares, equating to 149,554,017 shares[10] - The second-largest shareholder, Zeng Weixiong, held 13.42% of shares, totaling 53,769,291 shares, with 40,326,968 shares subject to lock-up[10] Other Income and Expenses - The company reported a significant increase in other income, which rose by 485.79% to ¥1,176,151.87, mainly due to the write-off of long-aged payables[8] - The company experienced a 140.88% increase in financial expenses, totaling ¥4,952,607.75, primarily due to increased bank loan interest expenses[7] - The company's long-term equity investments decreased by 86.73% to ¥1,866,761.26, primarily due to impairment losses recognized during the reporting period[6]
兰卫医学(301060) - 2024 Q3 - 季度财报